Skip to content

Clinical trials

Prostatic Neoplasms trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Prostatic Neoplasms Country / region: Italy Clear all

285 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20014
20022
20036
20044
20054
20064
20078
20087
20098
20108
20119
20125
201310
201416
201512
20165
201719
20188
201914
202020
202121
202217
202321
202414
202521
202614

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed132
Recruiting57
Unknown status37
Active, not recruiting36
Terminated15
Not yet recruiting6
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
IRCCS San Raffaele22
AstraZeneca14
Pfizer10
European Institute of Oncology9
European Organisation for Research and Treatment of Cancer - EORTC9
Regina Elena Cancer Institute9
Fondazione del Piemonte per l'Oncologia8
Bayer7
Bristol-Myers Squibb7
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Prostatic Neoplasms285
Neoplasms18
Breast Neoplasms16
Neoplasm Metastasis13
Ovarian Neoplasms9
Urinary Bladder Neoplasms9
Adenocarcinoma7
Colorectal Neoplasms7
Lung Neoplasms7
Carcinoma, Non-Small-Cell Lung6

Trials

Showing 26 to 50 of 285. Each trial links to its page on Pharma Observatory.

185 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.